Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$42.01 - $70.51
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.86M
Market Cap
$6.64B
Enterprise Value$9.06B
Total Cash (Recent Filing)$747.92M
Total Debt (Recent Filing)$1.51B
Price to Earnings (P/E)14.1
Beta0.58
Next Earnings
Aug 12, 2025EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding123,221,000
10 Day Avg. Volume1,612,427
30 Day Avg. Volume2,863,226
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)45.86
Price to Sales (P/S)0.00
P/FCF Ratio33.09
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue2.31
Enterprise Value/Gross Profit10.21
Enterprise Value/Ebitda3.73
Forecast
1Y Price Target
$65.67Price Target Upside23.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Halozyme News
Bulls Say, Bears Say
Bulls Say
Financial GuidanceHalozyme raised FY25 and multi-year guidance through 2028 to better reflect the growing momentum of multiple recent launches which remain underappreciated.
Market ExpansionApproval of Darzalex Faspro would mark the first medicine to treat smoldering multiple myeloma, which could significantly expand the market.
Product ApprovalThe European Commission granted approval to the subcutaneous version of Bristol-Myers Squibb's PD-1 inhibitor, Opdivo, which leverages Halozyme's ENHANZE to enable easier and faster administration.
Bears Say
Commercial RiskRisks include commercial risk with ENHANZE, particularly in the multiple myeloma indication, which is dynamic and rapidly evolving, and partnership risk, specifically with respect to Janssen.
Pricing RiskA research firm suggested that drugs using Halozyme's Enhanze additive may not be seen as new drugs, leading to potential earlier price negotiations.
Regulatory RiskHalozyme shares have tumbled due to a note from Leerink Partners interpreting recent draft guidance from the US CMS.
Ownership Overview
1.11% Insiders
32.03% Mutual Funds
23.92% Other Institutional Investors
12.52% Public Companies and Individual Investors
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $42.01 and its highest was $70.50 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $6.64B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Aug 12, 2025 which is in 54 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on May 06, 2025. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.924 by $0.186.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 1.21.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 123,221,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.11 in its last earnings report, beating expectations of $0.924. Following the earnings report the stock price went up 18.121%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
Halozyme Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.67 (23.65% Upside)
$65.67 (23.65% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 16.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.94%
12-Months-Change
Fundamentals
Return on Equity
147.06%
Trailing 12-Months
Asset Growth
19.28%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company based in the United States that specializes in developing and commercializing novel therapeutics aimed at enhancing the delivery of biologics and drugs. The company's core product offerings include its proprietary enzyme-based drug delivery platform, ENHANZE, which facilitates the subcutaneous administration of intravenous therapies, improving patient experience and treatment efficiency. Halozyme operates primarily within the biopharmaceutical sector, partnering with leading pharmaceutical companies to integrate its technology into their product pipelines.
HALO Company Deck
HALO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with significant growth in revenue and profits driven by key blockbuster products. The company announced new growth catalysts and an increased guidance for 2025. However, ongoing litigation with Merck poses a potential risk, though it is not expected to impact the core business. Overall, the highlights significantly outweigh the lowlights.Read More>HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
HALO Stock 12 Month Forecast
Average Price Target
$65.67
▲(23.65%Upside)
Technical Analysis
Corcept Therapeutics
―
Jazz Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Ascendis Pharma
―
Roivant Sciences
―